Trial reportRadiology2022
Impact of
Abstract readClinical Trial
In one paragraph
Trial report in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.Annals of nuclear medicine · 2025Pooled it
- Effect ofFrontiers in medicine · 2024Pooled it
- [18F]F-DCFPyL PET/MRI radiomics for intraprostatic prostate cancer detection and metastases prediction using whole-gland segmentation.The British journal of radiology · 2025Trial
- Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).Theranostics · 2026Review
- Application value of radiomics features based on PSMA PET/CT in diagnosis of clinically significant prostate cancer: a comparison between manual and automatic segmentation.BMC medical imaging · 2025Article
- PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications.World journal of urology · 2025Article
- Article
- Review
- Standardized classification schemes in reporting oncologic PET/CT.Frontiers in medicine · 2022Review
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Adriano Basso DiasFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).ORCID 0000-0003-4761-8708
Antonio FinelliFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).ORCID 0000-0003-4032-6120
Glenn BaumanFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).ORCID 0000-0002-5279-7360
Patrick Veit-HaibachFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).
Alejandro BerlinFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).ORCID 0000-0002-1880-6905
Claudia OrtegaFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).ORCID 0000-0003-3357-1849
Lisa AveryFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).ORCID 0000-0002-8431-5143
Ur MetserFrom the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).ORCID 0000-0003-3726-8994
Western University · CA
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Data regarding 2-(3-{1-carboxy-5-[(6-[
Indexed as
Positron Emission Tomography Computed TomographyProstatic NeoplasmsAgedHumansLysineMaleMiddle AgedNeoplasm StagingProspective StudiesPyridinesTomography, X-Ray ComputedUreaLysinePyridinesUrea
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.